A clinical trial to investigate VDA-1102 for the treatment of actinic keratosis (AK), an early form of cutaneous squamous cell carcinoma (cSCC)

Trial Profile

A clinical trial to investigate VDA-1102 for the treatment of actinic keratosis (AK), an early form of cutaneous squamous cell carcinoma (cSCC)

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs VDA 1102 (Primary)
  • Indications Actinic keratosis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 29 Jun 2016 Status changed from recruiting to completed, according to a Vidac Pharma media release.
    • 17 May 2016 New trial record
    • 25 Feb 2016 Status changed from planning to recruiting, according to a Vidac Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top